Maria Bishop, MD
Hematology & Oncology · Tucson, AZNPI 1841202785
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $538 of the $714 with a category attached, or 75.4%. Bristol Myers Squibb accounts for 75.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $607 and has fallen 91.3% since, to $53 in 2025. That places this record below the midpoint for hematology & oncology clinicians in AZ, where the typical reported total is $6,870.
Across 8 payments — averaging $89.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$538
- Varian Medical Systems, Inc.$54
- Teva Pharmaceuticals USA, Inc.$53
- Sanofi$24
- Takeda Pharmaceuticals U.S.A., Inc.$18
- Amgen$15
- plus $12 from 1 others
Across 2 payments — averaging $13,774 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$28K
What the payments were for
- Travel & lodging$53875%
- Food & beverage$16423%
- Education$122%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 1 | $538 |
| Varian Medical Systems, Inc. | 1 | $54 |
| Teva Pharmaceuticals USA, Inc. | 2 | $53 |
| Sanofi | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Amgen | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Revlimid$538
How this compares
$714 in reported general payments places this provider in the 20th percentile of 261 hematology & oncology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Everolimus | 18 | $15,051 |
| Dexamethasone | 14 | $270 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Tucson
- Christopher ChenTucson$370K
- Rachna ShroffTucson$250K
- Alison StopeckTucson$115K
- Jaspreet ChahalTucson$104K
- Basel ShouaTucson$98K
- Akshay AmaraneniTucson$93K
- Ahmed AbdelazizTucson$35K
- Michael BoxerTucson$30K
- Catherine AzarTucson$29K
- Ricklie JulianTucson$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.